INVISION - An Observational Study to Explore Effectiveness, Tolerability and Safety of Paliperidone ER in Patients With Schizophrenia

• Status: Completed
• Trial end date: 2009-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to explore efficacy, tolerability and safety of paliperidone Extended Release (ER) in 250 schizophrenia patients who started treatment with paliperidone ER in a naturalistic setting.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen-Cilag B.V.
• Treatments: Paliperidone Palmitate

Criteria

Inclusion Criteria:

• Patient meets the DSM-IV criteria for schizophrenia

• Switched to or started on paliperidone ER, not longer than two weeks ago

• In 24 hours before initiation of paliperidone ER treatment, CGI-S, patient satisfaction with treatment, concomitant therapy, body weight, GAF and HoNOS data are available

• Patient or legal representative has signed the informed consent form within two weeks after starting treatment with paliperidone ER

Exclusion Criteria:

• No use of paliperidone ER, clozapine, any conventional depot neuroleptic or long acting atypical antipsychotic drugs during 3 months before starting paliperidone ER

• No participation in an investigational drug trial in 30 days prior to starting paliperidone ER

• No history of neuroleptic malignant syndrome

• No known hypersensitivity to paliperidone ER or risperidone

• No patients hospitalized for a period longer than 12 weeks